Test Price
2,800 AED✅ Home Collection Available
BIN1 Gene Centronuclear Myopathy Type 2 Genetic Test in UAE | 2,800 AED | DHA Guidelines
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via ISO‑certified Next‑Generation Sequencing (NGS).
- Sample Logistics: VIP home phlebotomy (8 AM – 11 PM) with temperature‑controlled cold‑chain transport.
- Clinical Guidance: Post‑result teleconsultation with a Consultant Medical Geneticist.
- Insurance: Direct coverage check via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The BIN1 gene test screens for pathogenic variants causing Centronuclear Myopathy Type 2 (CNM2), a rare autosomal recessive congenital myopathy. Our NGS analysis delivers full‑gene coverage with 99.9% diagnostic sensitivity, enabling precise diagnosis, family risk assessment, and personalized management plans.
| Feature | Our NGS Test | Closest Alternative (Sanger / Single‑Gene Panel) |
|---|---|---|
| Methodology | Next‑Generation Sequencing (Illumina® platform, full BIN1 gene) | Sanger sequencing (usually limited to known familial variant) |
| Diagnostic Sensitivity | 99.9% (detects all coding exons ± flanking regions) | Variable; only tests specific point mutations |
| Turnaround Time | 3–4 weeks | 2–3 weeks (but limited scope) |
| Clinical Utility | Comprehensive – confirms diagnosis, carrier status, and recurrence risk | Confirmatory only if a specific variant is known in the family |
Physician Insight & Safety Protocols
“Centronuclear Myopathy Type 2 diagnosis requires both clinical suspicion and molecular confirmation. Our NGS assay provides comprehensive coverage of the BIN1 gene, but interpretation must always be integrated with a thorough neuromuscular evaluation and family pedigree. I recommend discussing results with your treating physician before any management or lifestyle changes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA: 9294403
Pre‑Test Advisory
A mandatory genetic counseling session is required before sample collection to document family history and obtain informed consent. The test is performed only after written consent per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Testing of minors without legal guardian consent; acute febrile illness (postpone collection); unwillingness to participate in genetic counseling.
- Emergency Red Flags: Sudden severe muscle weakness, difficulty breathing (diaphragmatic involvement), or inability to walk – seek immediate emergency care.
Patient FAQ & Clinical Guidance
1. What is the BIN1 gene test used for, and why might I need it?
The BIN1 gene test identifies mutations causative of Centronuclear Myopathy Type 2, a congenital muscle disorder characterized by hypotonia and progressive weakness. Clinical suspicion arises when an infant presents with floppiness, feeding difficulties, or delayed motor milestones; a positive result enables targeted neuromuscular care and accurate family planning.
2. How accurate is this genetic test, and what methodology is used?
Our NGS analysis achieves 99.9% diagnostic sensitivity by sequencing the complete coding region of the BIN1 gene with Illumina® technology. This surpasses older Sanger methods, detecting even rare intronic variants linked to CNM2. All results are interpreted by board‑certified clinical geneticists following ACMG guidelines.
3. What is the turnaround time, cost, and collection procedure?
Results are typically available within 3 to 4 weeks at a transparent, all‑inclusive price of 2,800 AED, with hospital‑grade home collection available from 8 AM to 11 PM daily. A certified phlebotomist visits your location; samples (whole blood, FTA card, or extracted DNA) are transported under strict cold‑chain protocols to our ISO‑accredited laboratory, ensuring sample integrity and patient convenience.
UAE Regulatory & Data Privacy Adherence
Data Protection: This service complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent is obtained per Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is processed securely and accessible only to authorized clinicians.
Clinical & Logistical Metadata
| Test Name | BIN1 Gene Sequencing – Centronuclear Myopathy Type 2 |
| Price (AED) | 2,800 AED (all inclusive) |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), FTA card, or extracted DNA – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina® platform, full gene coverage |
| ICD-10-CM Code | G71.2 (Centronuclear myopathy) |
| LOINC Code | 81315-1 (BIN1 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians